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Chapter 1  
Introduction 
The US population is aging
1
 and living longer. These twin phenomena are bringing with 
them increases in surgeries, surgery-related complications, and costs.
2-5
 Roughly, half of 
patients undergoing surgery take medications unrelated to surgery, with a significant 
increased risk of post-operative complications compared to patients taking no 
medications.
6
 Consequently, there is considerable potential for adverse drug reactions in 
the perioperative period. Current perioperative morbidity and mortality is frequently 
associated with patient medical co-morbidities and patient safety problems in the context 
of surgery or anesthesia. 
As a result, perioperative medicine- the consultation, care, and co-management of 
patients undergoing surgery- is becoming an ever-increasing area of clinical focus in 
primary care. A key step in the perioperative medicine process is providing medication 
management recommendations to patients and providers. These recommendations are 
decisions on stopping or continuing the patient’s medications prior, during and after a 
planned surgery. Due to the paucity of clinical research perioperative medication 
management recommendations are largely a provider-specific practice. Hence, practice 
variations exist in making the most appropriate recommendations in the perioperative 
setting. 
Clinical decision support systems (CDSS) are “active knowledge systems, which use two 
or more items of patient data to generate case-specific advice.” 7 This implies that a 
CDSS is simply a decision support system that is focused on using knowledge 
 2 
 
management in such a way to achieve clinical advice for patient care based on some 
number of items of patient data. CDS tools can help enhance doctor-patient 
communication
8
 and potentially improve workflow, efficiency, and patient outcomes. 
Clinical decision support systems are typically designed to integrate a medical knowledge 
base, patient data and an inference engine to generate case specific advice (Figure 1-1). 
Figure 1-1. Clinical Decision Support Components and outputs 
 
 
A 2005 systematic review by Garg et al 
9
 concluded that CDSSs improved practitioner 
performance in 64 of 100 studies. Sustainable CDSS features associated with improved 
practitioner performance include the following: 
 HIT systems can improve access to pieces of information, organize them, and 
identify links between them 
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 Clinicians often ‘know’ the information (e.g. drug–drug interaction) but forget to 
consider it 
 HIT systems are effective in bridging this ‘knowing–doing’ gap by presenting the 
relevant information to the clinician at the time of decision making
10
 
Medication management recommendations can effectively be thought of as guidelines. 
They are generally broad-based statements that apply to a general class of patients; 
however, patient specific criteria must be considered for the optimal application of a 
recommendation. The promise of guidelines, especially automated ones, to reduce 
practice variability and improve outcomes is great
11
,
 
and previous work has shown that 
computer-generated, patient-specific reminders can positively influence practice.
12 13
 As 
computers become standard tools of clinical practice, computer-based guidelines can 
increasingly be integrated into routine workflow, so that “clinicians can have more 
immediate access to the most current and relevant information at the time they most need 
it--when making clinical care decisions.” 14 
Furthermore, these recommendations are documented in EHR systems in free-text, 
unstructured format, making statistical analysis, indexing, storing, and timely retrieval of 
data practically intractable. Standardized structured terminology development will be 
useful to better understand the clinical work and associated clinical decisions in 
perioperative medication management. The meaningful use of EHRs aims to establish the 
effective use and exchange of health care information in order to support better decision 
making and more effective processes. In fact, Stage 2 of Meaningful Use of EHR systems 
recommends SNOMED CT 
15
 (Systemized Nomenclature of Medicine Clinical Terms) 
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for structured coding of clinical data in EHRs
16
. SNOMED CT is a comprehensive 
clinical terminology which provides a consistent way to index, store, retrieve, and 
aggregate clinical data across disparate specialties and health care facilities.  Expressing 
perioperative medication management recommendations in SNOMED CT can potentially 
help reduce practice variability in data capture and encoding. 
Two great opportunities exist to help improve patient outcomes in the perioperative 
setting: 1) utilizing Health Information Technology (HIT) to put medical information 
from trusted sources in the hands of providers by creating a CDSS to aid physicians with 
making drug management recommendations at the point of care; and 2) evaluating the 
use of structured clinical concepts in SNOMED CT for expressing perioperative 
medication management recommendations in order to make this clinical information 
computable, and thus usable, for efficient and more accurate population studies, 
outcomes research, and cost-benefit analyses. 
Study Objectives 
The overall research project described here consists of three studies. In the first two 
studies we utilized fundamental principles in clinical informatics combined with 
qualitative and quantitative methodologies to design, develop, and evaluate a medication 
management recommendation CDSS. This system would be deployed during a pre-op 
physical exam evaluation when the patient’s medications are reviewed and decisions on 
stopping or continuing them prior to surgery are made. In the first study we developed the 
necessary heuristics (rule-based system) to provide the foundation for an eventual CDSS 
in perioperative medication management. The heuristics were developed using 
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methodical searches of trusted medical sources. To vet the knowledge within, and results 
of relevant studies, we enrolled domain experts in perioperative medicine to provide 
context as well as interpretation of study findings. The “rules” file containing the 
heuristics was developed with the portable XML markup language, using established 
literature search techniques on trusted medical sources. In the second study we designed, 
developed and evaluated a medication management recommendation system from the 
rules engine in the previous study and other web-based software components. In the final 
step of this study, we evaluated the accuracy and performance of the tool with a test set of 
actual, annonymized patient cases. 
In the third and final study we incorporated inter-rater reliability and questionnaires to 
evaluate the use of a standard terminology for expressing medication management 
recommendations in a structured, portable, and computable format. Because those 
components of the EHR demonstrated to improve quality (e.g. Computerized Provider 
Order Entry (CPOE) and CDSSs) depend on the ability of EHRs to code clinical data in a 
structured and standardized format
17-19
, the ability to improve quality of medication 
management recommendations is contingent upon the use of standardized terminologies 
as a prerequisite to improving health outcomes.
 
In what follows this introduction details of these studies will systematically discuss and 
achieve the following objectives: 
1. Collecting, analyzing, and vetting medication management recommendations 
from trusted medical sources 
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2. Building and evaluating a decision support system based on Objective 1 
3. Evaluating the use of existing structured terminology standards to express 
medication management recommendation concepts 
Using pharmacy data, evidence-based literature, and expert panel opinions, these three 
studies serve to fill fundamental gaps in two critical areas: 1) making the best known 
medication management recommendations in the preoperative setting; and 2) the 
feasibility of using structured clinical terms to express medication management 
recommendation concepts currently documented in free-text style. Our studies can serve 
as a blueprint for constructing and evaluating future systems in similar environments. The 
ultimate goal of this project is helping to improve patient outcomes by creating a decision 
support system and utilizing structured data to assist in making clinical decisions and 
creating more accurate patient data. 
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 (Abstract accepted for the Symposium) 
 
Introduction and Background: Decisions regarding medication management during the 
perioperative period are often made based on clinical anecdotes and vary by provider. 
Clinical decision support (CDS) tools aid physicians with decision making tasks at the 
point of care. We have developed a set of perioperative medication management 
recommendation decision heuristics based on evidence-base literature, clinical notes, 
and expert opinions. These heuristics will serve as the foundation for a subsequent CDS 
tool in perioperative medicine.  
Methods: In this descriptive study, we manually extracted key demographic and 
medication-related data from the records of 100 randomly-selected patients at the 
Minneapolis VA’s preoperative medicine clinic. We then searched PubMed for studies in 
perioperative medication management as well as other web sources for expert opinions 
in the field. Relevant studies, clinical notes, and expert opinions were distilled into an 
XML-based set of heuristics “rules” file. 
Results: We have developed medication management recommendation heuristics for the 
entire VA’s formulary of drugs based on evidence-base literature, actual clinical notes, 
and expert opinions.  
 
Discussion and Conclusion: This work shows a proof of concept for the full-scale system 
development of similar decision support systems. 
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Background 
Decision making in medicine is complex because a substantial amount of knowledge is 
required even to solve seemingly simple clinical problems.
20
 A physician is required to 
remember and apply the knowledge of a large array of entities such as disease 
presentations, diagnostic parameters, drug combinations and guidelines.
21
 However, the 
physician’s cognitive abilities are challenged by factors such as multi-tasking, limited 
reasoning, and memory capacity.
22 23
 These challenges are particularly difficult in 
perioperative medicine, where providers must recall large amounts of information and 
process clinical data spanning multiple clinical specialties.
24
 With an aging population 
1
 
there has been a substantial increase in the number of surgeries, surgery-related costs, and 
complications from surgery.
2-5
 At least 50 percent of patients undergoing surgery take 
medications on a regular basis 
6
, and as many as 44% take one or more medications prior 
to surgery.
25
 Furthermore, half of the general surgical patients take medications unrelated 
to surgery, with a significantly increased risk of post-operative complications compared 
to patients taking no medications.
6
 With the induction of anesthesia – sometimes with the 
introduction of ten or more drugs- the probability of an adverse drug interaction increases 
substantially with the number of drugs a patient receives.
26
 Consequently, there is 
considerable potential for adverse drug reactions in the perioperative period. Current 
perioperative morbidity and mortality is frequently associated with patient medical co-
morbidities and patient safety problems in the context of surgery or anesthesia.  
Although the surgical burden in the U.S. is increasing, some perioperative medicine 
providers feel that they are inadequately trained to perform preoperative evaluations.
27
 
Unfortunately, there is limited outcome data related to the majority of medications taken 
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in the perioperative period, and few controlled trials regarding perioperative medication 
discontinuation and resumption, so decisions regarding medication management are often 
made based on pharmaceutical manufacturer recommendations, expert consensus, in vitro 
studies, or clinical anecdotes.
28
 This lack of medical evidence is reflected by the large 
variation in perioperative medication management recommendations among providers.
29-
31
  
On the other hand, clinical decision support systems (CDSS) aid health care professionals 
with decision making tasks at the point of care.
32
 These systems provide evidence-based 
knowledge in the context of individual patient parameters.
7
 CDSSs have been shown to 
be effective tools in aiding with providing alerts and reminders
33
, computerized provider 
order entry (CPOE) support
34
, and making recommendations.
35 36
 The popularity and 
usage of CDSSs have been growing due to the evidence that they improve clinical 
practice and physician performance.
9 37
 
Rule-based expert systems are a special class of CDSS in which computers emulate the 
decision-making ability of a human expert.
38
 The building, maintenance and development 
of expert systems is known as knowledge engineering,
39
 a “discipline that involves 
integrating knowledge into computer systems in order to solve complex problems 
normally requiring a high level of human expertise”.40 Expert systems (Figure 2-1) have 
three basic components
32
: 
1. Knowledge Base: a set of expertise supplied by domain experts 
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2. Inference Engine: the component which processes the knowledge (heuristics) 
furnished by domain experts. Domain expert inputs are translated to a 
representation system of concepts by a knowledge engineer (i.e. the 
informatician) who then supplies them to a programmer who writes the software 
based on the concepts in a specific programming language 
3. User Interface: The “visible” part of the system with which users interact to solve 
a particular problem. 
Figure 2-1. An Expert system and components 
 
We have a unique opportunity to build the foundations of informatics in Perioperative 
Medication Management (PMM) by collating the knowledge (decisions on managing 
medications prior to surgery) from evidence-based literature, expert opinions, and actual 
patient notes and distilling this knowledge into a set of clinically actionable decision 
heuristics. Based on the heuristics, we can then build the necessary CDS tools for PMM 
to help improve the practice of perioperative medicine 
41
 and potentially improve patient 
outcomes.  
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Methods and Materials 
Institutional approval was sought and deemed not necessary for this descriptive study, 
with the activities in the project being deemed quality improvement in their nature.  
Philosophy 
PMM is a complex clinical task and the provision of decision support in this complex 
web has a number of inherent challenges. We chose to be guided by the philosophy of 
primum non nocere (“first, do no harm”) in providing recommendations when to stop or 
continue a medication. Medications associated with known morbidity when stopped 
abruptly should be continued. 
42
 Medications believed to increase the risk of surgical 
complications that are not essential for short-term improvement in quality of life 
43
, or 
medications thought to interact negatively with anesthetic agents should be stopped 
perioperatively. Clinical judgment should be exercised in other cases where the clinical 
evidence and drug mechanisms of action do not give clear guidance for definitive 
decision making. In this work, medication is defined to include: prescribed medications, 
over-the-counter medications, supplements, and herbal products.  
Study Goal  
Our over-arching goal in this project was to improve PMM by promoting safe and 
effective use of medications. To achieve this goal we sought to identify clinical 
knowledge sources to supply our heuristics engine with the necessary know-how that 
later will become a working CDSS for PMM. 
Study Scope 
It is beyond the scope of this study to investigate all aspects of perioperative medicine 
use or to develop a clinical data set for all perioperative medications; hence, the authors 
 12 
 
decided to focus on developing a set based on the Veterans Affairs National Drug File 
(NDF), a centrally maintained electronic drug list used by the Veterans Health 
Administration (VHA) hospitals and clinics.
44
 Since the NDF is updated frequently by 
the VHA, we froze the version with which we worked to the revision released in June 
2011. This represents a substantial medication formulary of about 12,000 unique drugs 
used in the treatment of 8 million veterans in the VHA clinical system. 
Setting 
The study was conducted at the Preoperative Medicine Clinic of the Veterans Affairs 
Medical Center (VAMC) in Minneapolis, Minnesota. The Clinic is composed of 10 
clinical providers with a 90% adult male, and 10% adult female patient population. 
Providers and other clinicians use the enterprise-wide VistA Electronic Health Record 
(EHR) system for clinical care.  
Design and Implementation 
Knowledge Management 
Before developing the medication management heuristics, we took the initial step of 
developing a model to formally represent the knowledge within the domain of PMM by 
constructing the PMM Ontology of Concepts and Relationships (Figure 2-2). With the 
help of an ontology, the knowledge is not only human readable, but also computer-
interpretable.
45
 The development of the ontology followed standard techniques
46
 and with 
consultation with two expert team members (TA, SS). The ontology provided a structural 
framework for the organization and use of clinical information and helped capture the 
flow of information and data. For instance, with the help of the ontology’s architecture, 
the team quickly discovered that drug actions are often contextually influenced by 
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medication type, surgery risks, laboratory and imaging results, and co-morbidities noted 
in the patient’s record.  
Figure 2-2: Perioperative medication management Ontology of Concepts and Relationships 
 
Data Collection and Sources 
This was a retrospective descriptive study using records of 100 randomly-selected 
patients seen at the preoperative medicine clinic between 8/1/2010 and 7/31/2012 
representing 1,272 medication assessment and management decisions. Each patient had 
been given a comprehensive history and physical exam prior to surgery. Due to the 
relative paucity of females compared to males in the study population, female patients 
were oversampled to better represent a typical clinical population. The distribution of 
 14 
 
patients per gender per provider is given in Table 2-1. The minimum age (Female/Male) 
and maximum age were (27/27) and (75/87), respectively.  
Table 2-1: Per-provider patient gender distribution 
Provider No. of Female Patients No. of Male Patients Total 
P1 
 
15 14 29 
P2 
 
3 12 15 
P3 
 
16 10 26 
P4 
 
16 14 30 
Total 50 50 100 
 
From each patient record, the following data fields were manually extracted and entered 
into a clinical database for heuristics development: Surgery, Active Medications, 
Medication Management Recommendations (actions), as well as INR (International 
Normalized Ratio- a measure to test how fast blood clots) and Creatinine lab values. INR 
and Creatinine values were chosen by the clinical reviewers as important data points for 
their significance in reflecting the overall liver and kidney health and ability to 
metabolize and excrete drugs.
47
 Surgical procedure types were collected and stratified to 
nominal risk categories of bleeding risk, poor wound healing risk, and risk of infection. 
See Table 2-2 for sample data points collected from one patient record. 
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Table 2-2: Sample data points taken from one patient record 
Patient Medication Action 
 
ID: 000 
Male 
Age: 68 
Surgery: Left Total Knee Arthroplasty 
Creatinine: 0.7 
INR: 1.05 
Medication: DOXYCYCLINE HYCLATE 100MG 
Medication: FISH OIL 1000MG 
Medication: ALBUTEROL 90MCG (CFC-F) 
 
Medication: GABAPENTIN 300MG 
 
 
 
 
Take A.M. of surgery 
Hold 7 days prior to surgery 
Take 30-60 minutes before 
surgery 
No recommendation provided 
 
Supporting Evidence  
Medication management recommendation knowledge was extracted from evidence-based 
literature, expert opinions, and public web sources. With advice from two reference 
librarians, the following search terms were entered as keywords and MeSH terms into 
PubMed
®
: 
Drug Name (N); Drug Category (C); perioperative care (p); perioperative period (pʹ); 
anesthetic (a); anesthetics (aʹ). We combined the above search terms in the following 
combinations and looked within each set Si for relevant articles: 
S1 = (N   C)   (p   pʹ) 
S2 = N   (a   aʹ) 
S3 = C   (a   aʹ) 
Google, Google Scholar, UpToDate®, and DynaMed were also searched with the search 
term “perioperative medication management”. Additional information required to 
complete or enhance the results was obtained through specific searches and perusal of 
reference lists of retrieved articles and “cited by” links (see Table 2-3). 
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Table 2-3: Supporting sources and types of evidence 
Knowledge 
Source  
Physical Source Comments 
   
Evidence-Based  
 
Literature 
PubMed 
 
Authoritative textbooks in 
perioperative medicine and 
anesthesiology24 48 49 
 
Select, peer-reviewed journal articles 
 
Select chapters or sections 
   
Expert Opinions Medical domain experts, UpToDate®, 
DynaMed, Google, Google Scholar 
 
Editorials, case presentations, comments, etc. 
   
 
Drug Decisions 
We enrolled three physicians trained in general internal medicine to review the sample 
data and make medication management recommendations for each patient. We recorded 
each reviewer’s recommendations and compared it to the actual recommendation in the 
EHR notes. If the recommendation matched, we marked it as agreeable; otherwise we 
noted the decision as disagreeable. Lastly, we computed agreement percentages between 
the reviewers’ recommendations and the EHR notes. To identify correlations between 
drug categories and actions, medications were further grouped by category as defined in 
VA’s Class Index file.50 We did this as to enable us to make medication 
recommendations at the category level as much as possible, instead of the untenable task 
of making decisions at the individual drug level. We also noted any exceptions (different 
actions) within individual categories. For instance, while ASPIRIN and 
ACETAMINOPHEN were both in the NON-OPIOID ANALGESICS category, the 
action recommended for each would be different. Exceptions were discovered during the 
literature search or in consultation with domain experts during the review process. 
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We defined “evidence-backed” drugs as those with: 
 the same decision in the EHR notes and by all the reviewers, at least 80% of the 
time, averaged across all patients taking the drug  
OR 
 less than 80% inter-rater agreement for decision, but adjudicated by a 4th domain 
expert 
OR 
 supporting evidence from evidence-base literature  
For example, in Table 2-4, the drug INSULIN,ASPART,HUMAN has the action “Hold A.M. of 
surgery” with an overall inter-rater agreement of 93.75%. Drugs with less than 80% agreement 
were classified as “Indeterminate” and were further adjudicated by additional domain expert 
reviewers. We created a list of drug categories that were not in our sample records and solicited 
the assistance of one of the authors (SS) to review and choose two prototypical drugs from each 
category. We then provided this list to two domain experts and asked them to record their 
recommendations for each drug in the list. All discrepancies in recommendations at this step were 
adjudicated by three additional domain experts. Actions that could not be agreed upon even after 
further review were marked as “no consensus/standard of care” recommendations. 
Table 2-4: Sample drug and its management recommendations 
 
ID Drug Category Notes Expert 1 Expert 2 Expert 3 % Agreed 
 
44 
 
INSULIN,ASPART, 
HUMAN 
 
INSULIN 
 
Hold A.M. 
of surgery 
 
Hold A.M. 
of surgery 
 
Hold A.M. 
of surgery 
 
Hold A.M. 
of surgery 
 
 
100 
2023 INSULIN,ASPART, 
HUMAN 
INSULIN  --- Hold A.M. 
of surgery 
Hold A.M. 
of surgery 
Hold A.M. 
of surgery 
 
75 
3050 INSULIN,ASPART, 
HUMAN 
INSULIN  Hold A.M. 
of surgery 
Hold A.M. 
of surgery 
Hold A.M. 
of surgery 
Hold A.M. 
of surgery 
 
100 
4037 INSULIN,ASPART, 
HUMAN 
INSULIN  Hold A.M. 
of surgery 
Hold A.M. 
of surgery 
Hold A.M. 
of surgery 
Hold A.M. 
of surgery 
 
100 
       93.75(mean)   
 
The following is a list of actions extracted from sample records: 
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 Take A.M. of surgery  
 Take P.M. prior to surgery 
 Take m minutes before surgery 
 Take perioperatively 
 Take a reduced dose n [hours/days/weeks] before surgery 
 Take a varied dose n [hours/days/weeks] before [and/or after] surgery 
 Hold A.M. of surgery  
 Hold P.M. prior to surgery 
 Hold perioperatively 
 Hold for n [hours/days/weeks] days before surgery  
 Hold for n [hours/days/weeks] before and after surgery  
 
Heuristics Implementation 
We structured the heuristics in XML schemas “rules” file in order to optimize access to 
information and resources that incorporates relevant clinical concepts. XML provided a 
hierarchical structure to store information (e.g. categories, drugs, exceptions, 
recommendations) in a web-based, platform-independent manner. Furthermore, instead 
of being in vendor-specific non-human readable binary format, the rules file is machine 
as well as human readable 
51
 making it very easy for debugging, software maintenance, 
and data exchange. This file contains drug action heuristics for the entire VA drug 
formulary and provides decisions (recommendations) for each drug based on a tiered 
supporting evidence structure (see Figure 2-3).  
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Figure 2-3: Evidence types and levels 
 
Figure 2-4 shows how categories, drugs, and actions are coded in this portable form. 
Each action, when supported by evidence, has a link to the evidence as well as the level 
of the evidence. 
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Figure 2-4. A category-level medication management recommendation in XML with exception handling and 
supporting evidence level and evidence hyperlinks                       
<drugclass> 
<id>AN300</id> 
 <instructions>No action recommended</instructions> 
 <exception> 
  <drug> 
   <name>METHOTREXATE NA 2.5MG TAB</name> 
   <instructions> If creatinine is normal, safe to continue, otherwise hold 7-14 days prior: 
&lt;a 
href=&quot;http://www.ncbi.nlm.nih.gov/pubmed/?term=11171680+17204310
&quot;target=_newpage;&gt; SUPPORTING EVIDENCE 
&lt;/a&gt;&lt;p;&gt;If minor surgery, safe to continue: &lt;a 
href=&quot;http://www.ncbi.nlm.nih.gov/pubmed/?term=20033813&quot;targ
et=_newpage;&gt; SUPPORTING EVIDENCE &lt;/a&gt;&lt;/p;&gt;  
Evidence Level: B 
    </instructions> 
  </drug> 
 </exception>  
</drugclass> 
 
Results  
Table 2-5 depicts the drug burden statistics in the sample population. 
Table 2-5: Drug burden frequencies in the sample population 
Gender Count Mean 
Age 
No. of 
drugs 
Mean No. of drugs 
(SE) 
Median No. of 
drugs 
Mode of No. of 
drugs 
Female 
 
50 50 430 8.60 (0.88) 7 12 
Male 50 64 584 11.68 (0.89) 11 15 
Total 100 57 1014 10.14 (0.64) 9 8 
 
Overall, our sample population used 252 unique drugs from 122 categories. The 
distribution of patient chart-reviewed actionable drug categories, associated 
recommendations, and the mean agreement percentage among the reviewers and the EHR 
notes is given in Table 2-6. 
  
Exception drug member 
Sources of evidence 
Drug class 
Default recommendation 
Exception recommendation 
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Table 2-6: Patient chart-reviewed actionable drugs and recommended actions. †Consensus < 80% threshold, 
action determined by evidence-base literature or external adjudicator. ‡Exceptions exist within the category, see 
the rules file for details. *Consensus >= 80% threshold, but different from evidence-base literature; action from 
literature chosen 
Drug Category (n) Class 50 Action Mean 
Percent 
Agreement  
Evidence 
Level 
References 
ACE INHIBITORS (16) CV800 Hold A.M. 
of surgery  
 
86 A 52-58 
ANGIOTENSINII INHIBITOR (10) CV805 Hold A.M. 
of surgery 
 
70† B 52 54-56 59 60 
ANTIANGINALS (2) CV250 Take A.M. 
of surgery  
 
100 B 61 
ANTIARRHYTHMICS (1) CV300 Take A.M. 
of surgery‡ 
 
100 A 62 
ANTICOAGULANTS (1) BL110 Hold 5-7 
days before 
surgery‡ 
 
100 A 63-78  
ANTICONVULSANTS (31) CN400 Take A.M. 
of surgery 
 
90 C 79 
ANTIDEPRESSANTS,OTHER (SSRI’s) 
(46) 
CN609 Hold 1-5 
days before 
surgery‡ 
 
84 B 80-86 
ANTIDOTES/DETERRENTS,OTHER (7) AD900 Hold peri-
operatively‡ 
 
96 A 87 
ANTIGOUT AGENTS (1) OP109 Take A.M. 
of surgery 
 
100* C  
ANTIHYPERTENSIVE COMBINATIONS 
(5) 
CV400 Hold A.M. 
of surgery‡ 
 
90 A 62 88 
ANTIHYPERTENSIVES, OTHER (1) CV490 Take A.M. 
of surgery‡ 
 
100 C  
ANTI-INFLAMMATORIES,RECTAL (2) RS100 Hold 1 day 
before IBD 
surgery 
 
100* B 89 
ANTILIPEMIC AGENTS (non-statins) (9) CV350 Hold A.M. 
of surgery‡ 
 
83* B 90 91 
ANTILIPEMIC AGENTS (Statins) (41) CV350 Take A.M. 
of surgery 
 
96 A 92 
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ANTIMALARIALS (2) AP101 Take in 
outpatient 
surgeries 
with 
expected 
quick 
recovery 
 
75†* B 93 
ANTINEOPLASTICS,ANTIMETABOLITES 
(2) 
AN300 Hold 14 
days before 
major 
surgery if 
Creatinine 
level 
abnormal‡ 
 
63† A 94 95 
ANTIPARKINSON AGENTS(4) CN500 Take 
perioperativ
e 
-ly 
 
88* B 96-98 
ANTIRHEUMATICS, OTHER (1) MS190 Hold 7 days 
before 
surgery and 
7 days after 
surgery‡ 
 
100 B 24 
BETA BLOCKERS/RELATED (28) CV100 Take A.M. 
of surgery 
 
94 B 99-101 
BRONCHODILATORS, 
ANTICHOLINERGIC (5) 
RE105 Take A.M. 
of surgery 
 
76† B 48 
BRONCHODILATORS, 
SYMPATHOMIMETIC, INHALATION 
(27) 
RE102 Take A.M. 
of surgery 
 
75† C 91 
CALCIUM CHANNEL BLOCKERS (11) CV200 Take A.M. 
of surgery‡ 
 
86 B 102-104 
CARDIOVASCULAR AGENTS,OTHER 
(2) 
CV900 Take A.M. 
of surgery‡ 
 
75† B 105 
CONTRACEPTIVES,SYSTEMIC (5) HS200 Hold 4-6 
weeks 
before 
surgery‡ 
 
65† B 91 106 
ESTROGENS (5) HS300 Hold 4-6 
before 
surgery 
 
65† B 107-109 
GASTRIC MEDICATIONS,OTHER (42) GA900 Take before 
surgery‡ 
 
82 B 110-113 
GENITO-URINARY AGENTS,OTHER (11) GU900 Hold 7 days 
prior to 
surgery 
 
91* B 49 114 
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GLUCOCORTICOIDS (6) 
 
HS051 Vary dose‡ 
 
67† B 91 115 
HERBS/ALTERNATIVE THERAPIES (52) HA000 Hold 7 days 
before 
surgery 
 
93 B 116-119 
HISTAMINE ANTAGONISTS (12) GA301 Take A.M. 
of surgery 
 
81 B 120 121 
HORMONES/SYNTHETICS/MODIFIERS, 
OTHER (5) 
HS900 Hold 1-6 
weeks 
 before 
surgery‡ 
 
80 B 122 
INSULIN (quick-acting) (4) HS501 Hold A.M. 
of surgery 
 
94 B 123 124 
INSULIN (intermediate-acting) (3) HS501 Take 50% of 
usual dose 
 
92 B 123 124 
INSULIN (long-acting) (6) HS501 Take 50% of 
usual dose 
 
83 B 123 124 
LOOP DIURETICS (8) CV702 Hold A.M. 
of surgery‡ 
 
88 B 24 88 
NICOTONIC ACID (4) VT103 Hold 1 day 
before 
surgery 
 
81 B 24 
NONSALICYLATE NSAIs, 
ANTIRHEUMATIC (48) 
MS102 Hold 5-7 
days before 
surgery 
 
92 B 76 125-129 
OPIOID ANALGESICS (31) CN101 Hold prior to 
surgery 
 
94* B 130 
ORAL HYPOGLYCEMIC AGENTS, ORAL 
(Sulfonylurea) (11) 
HS502 Hold P.M. 
prior to 
surgery 
 
84 B 124 
ORAL HYPOGLYCEMIC AGENTS, ORAL 
(Biguanide ) (13) 
HS502 Hold 36 
hours before 
and after 
surgery 
 
98 B 124 
PLATELET AGGREGATION 
INHIBITORS (3) 
BL117 Hold 5-7 
days before 
surgery‡ 
100 A 65 66 68 70-73 
75-77 126 131-
140 
POTASSIUM SPARING/COMBINATIONS 
DIURETICS (3) 
 
CV704 Hold A.M. 
of surgery 
 
83 C  
SALICYLATES, ANTIRHEUMATIC (52) MS101 Hold 7 days 
before 
surgery‡ 
 
93 A 68 70-73 75-77 
126 131-140 
THIAZIDES/RELATED DIURETICS (11) CV701 Hold A.M. 
of surgery 
 
75† B 88 
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Table 2-7 contains the distribution of non-chart-reviewed actionable categories and the 
corresponding recommendations. 
  
THYROID SUPPLEMENTS (10) HS851 Take A.M. 
of surgery 
 
90 C  
TRICYCLIC ANTIDEPRESSANTS (8) CN601 Hold 7 days 
before 
surgery for 
low-dose 
patients‡ 
 
97 B 141 
VITAMIN E (5) VT600 Hold 7 days 
before 
surgery 
100 B 142 143 
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Table 2-7: Non- chart-reviewed actionable drugs and recommended actions. ‡Exceptions exist within the 
category, see the rules file for details. 
Drug Category Name  
Drug 
Class
50
 Action 
Evidence 
Level References 
 
ANTINEOPLASTICS, ALKYLATING 
AGENTS 
 
 
AN100 
 
Hold 1 week before 
surgery 
 
 
C 
 
OPIOID ANTAGONIST ANALGESICS CN102 Wean off if opioid will 
be given for pain 
control post-op 
 
C  
NON-STEROIDAL ANTI-
INFLAMMATORY ANALGESICS 
CN104 Hold 5 days before 
surgery, or 10 days if 
Creatinine level 
abnormal 
 
A 
76 125-129 
MONAMINE OXIDASE INHIBITOR 
ANTIDEPRESSANTS 
CN602 Hold per anesthesia 
preference‡ 
 
B 
144
 
DIGITALIS GLYCOSIDES CV050 Take A.M. of surgery C  
DIRECT RENIN INHIBITOR CV806 Hold the evening prior 
and A.M. of surgery 
 
C  
HYPOGLYCEMIC AGENTS, OTHER HS509 Hold A.M. of surgery if 
surgery in the 
afternoon; Hold PM 
prior if surgery in the 
morning 
 
B 
124
 
BRONCHODILATORS, 
SYMPATHOMIMETIC,ORAL 
 
RE103 Take A.M. of surgery C  
BRONCHODILATORS, XANTHINE-
DERIVATIVE 
 
RE104 Take A.M. of surgery C  
OPIOID-CONTAINING 
ANTITUSSIVES/EXPECTORANTS 
RE301 Hold 1 day before 
surgery 
C  
 
 
In consultation with two team members (TA and SS), we excluded 172 categories from 
the study. The eliminated categories included but are not limited to: 1) non-patient-
administered drugs; 2) durable medical equipment (DME); 3) corrective vision products; 
4) eyewashes; 5) sun protectants; 6) emollients; 7) personal and dental hygiene products; 
8) dental products; 9) enteral nutrition products; 10) some topical products (Figure 2-5). 
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For a complete list of the eliminated categories see Appendix 1. The resulting data file 
contains over 9,000 drugs in 409 categories. 
Figure 2-5: Sources of supporting evidence for medication management recommendations. E.B.L: Evidence-Base 
Literature; E.O: Expert Opinion; n=number of drug categories 
 
Discussion 
In this work we have shown the methodology and framework for building a CDSS 
knowledge engine. To the best of our knowledge this work is a first attempt at developing 
a heuristics-based rules engine for drug-based decision support. Because it is written in 
XML format, the rules file can be transported to any perioperative medicine healthcare 
facility and operationalized as part of a CDS tool with minimal effort. The knowledge 
engine contains heuristics for medication management recommendations covering 
approximately 10,000 drugs in 237 categories in the VA’s formulary. While not complete 
in developing decisions for all drugs, the work presented shows a proof of concept for the 
full-scale system development of similar decision support systems by replicating the 
 27 
 
methodology described here. This work will be used as the knowledge engine in a future 
perioperative medicine CDS tool.   
Physicians and informatics specialists were involved in the design and accuracy of 
clinical information system. The team chose from a catalog of expert rules that were 
supported by expert panels, guidelines, or clinical evidence. The design process ensured 
that each expert rule followed evidence-based guidelines and was programmed to 
automate steps in planning and delivering patient care. 
As with all evidence-based decision making, clinical judgment and experience factors 
into the process. This heuristics system is no exception. Given the scanty nature of strong 
scientific evidence supporting perioperative medication management decision-making, 
the development of this system also relied upon clinical experience and judgment in order 
to stratify the multiple risk factors as well as provide guidance along the medication 
decision pathway.  
It should be kept in mind that in addition to the medication’s inherent pharmacological 
characteristics the patient’s clinical status, as well as the surgical procedure also 
influences the decision to stop or continue a medication. Risks pertaining to each drug 
should be carefully evaluated. For example, several drugs can affect coagulation and 
discontinuation of others can lead to withdrawal symptoms with both cases leading to 
potential pre- and post-surgical clinical complications. 
Our work provides an evaluation of the potential problems and proposed approach to 
perioperative medication decision making using a national medication formulary. 
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However, our findings are limited in that many of our experiences to date come from a 
single, large, tertiary care institution; the practice patterns and clinical co-morbidities and 
patient populations at other types of institutions may vary from our findings. Other 
clinical formularies may also contain a broader set of medications to manage which 
would need to be evaluated prior to system implementation outside a VHA setting. 
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Chapter 3  
PeriMed: Development and Evaluation of a Perioperative Medicine 
Decision Support Tool 
 
Mehrdad Rafiei, MA
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Target Publication: Perioperative Medicine 
Background: A clinical decision support tool to manage medications can help 
perioperative medicine clinicians avoid spending valuable time looking for drug 
management information during a pre-op physical exam evaluation. Our objective was to 
develop and validate a clinical decision support (CDS) tool for managing medications 
perioperatively. 
Methods: We developed a CDS tool based on a set of heuristics classifiers developed in a 
previous study, and tested the tool using medication data extracted from the electronic 
records of 100 randomly selected perioperative medicine patients including medications 
in use. For each medication, the tool-generated recommendation was compared with 
actual recommendations in the EHR by experienced preoperative medicine providers. 
Results: A total of 879 medications were used by the sample population. We extracted 
378 “actionable” drugs from the EHR Notes section, compared to 479 identified by the 
tool, while 334 were identified in both. The total number of “non-actionable” drugs in 
the EHR notes was 132 compared to 18 flagged by the tool, while 369 were identified by 
both. In the initial testing phase the tool generated provider-matched recommendations 
76% of the time. After correcting for errors and adjudicating the differences by a 
perioperative medicine domain expert, the tool’s matching performance increased to 
95%. These results are encouraging. 
Conclusion: The CDS tool compared favorably with other similar tools and thus can be 
used as a support tool at the point of care.  
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Background 
There has been an increased emphasis on the use of clinical decision support systems 
(CDSS) to improve the quality of health care.
145
 The main objective in using CDSSs is to 
provide patient-specific recommendations generated through a comparison of patient 
information with clinical knowledge sources.
9 146
 In general, CDSSs can enhance clinical 
effectiveness by improving the quality of care
147
 and patient outcomes by aiding health 
care providers in the decision making process.
148 149
 As a technology tool, CDSSs can be 
utilized to align clinical decision making with best practices and the latest guidelines at 
the point of care and provide a potential means to change clinical practice. When these 
systems are used effectively they can reduce workload and help improve health care 
quality, efficiency, and outcomes.
150
  
During the course of a preoperative physical examination the provider needs to review, 
document, manage the usage and dosage, and potentially administer the patient’s various 
medications. This includes the clinical indication and therapeutic need for each 
medication; the effect on the primary disease of stopping a drug; drug pharmacokinetics 
and changes in the perioperative setting; potential adverse effect of the medication on 
perioperative risk (e.g. bleeding, hypoglycemia); potential benefits of starting a drug 
prophylactically (e.g. prevention of ischemia, thrombosis, infection, aspiration); and 
potential drug interactions with anesthetic agents. Considering these variables and a risk-
benefit analysis, the consulting provider must decide whether to continue, discontinue, or 
modify the regimen for each medication based on the patient’s characteristics. Although 
the surgical burden in the U.S. is increasing, some perioperative medicine providers feel 
that they are inadequately trained to perform preoperative evaluations.
27
 Unfortunately, 
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there is limited high quality outcome data related to the majority of medications taken in 
the perioperative period. Furthermore, very few controlled trials regarding perioperative 
medication discontinuation and resumption have been conducted. Consequently, 
decisions regarding medication management are often made based on pharmaceutical 
manufacturer recommendations, expert consensus, in vitro studies, or clinical 
anecdotes.
28
 This lack of evidence is reflected by the large variation in perioperative 
medication management recommendations among providers.
29-31
 A critical foundation for 
improving the way technology and information resources support perioperative clinicians 
would be an enhanced knowledge set which is developed to support perioperative care.
41
 
Developing health service interventions that address medication management decision 
making challenges are essential for reducing practice variability and potentially 
improving patient outcomes. A decision support system may provide such an 
intervention.
151 152
 Ideally, capture of coded clinical information can be linked to the 
knowledge of evidence-based medicine to provide tailored recommendations at the point 
of care and close the gap between best evidence and actual practice.
153 154
 Many studies 
have shown beneficial effects of CDSS on clinical decision making.
9 12 35 155-157
 The key 
tools for closing this gap will be information systems that provide decision support to 
medical consultants at the time the point of care to optimize clinical quality of care. 
Furthermore, in the current health care system, scientific knowledge about best care is not 
applied systematically or expeditiously to clinical practice. An average of nearly 17 years 
is required for new knowledge generated by randomized controlled trials to be 
incorporated into practice.
154
 Having clinically meaningful decision support may help 
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reduce the timing of adoption. In this article we will lay the foundations for such a 
decision support system. 
An immediate and effective way to help collate and extract new knowledge in 
perioperative medication management (PMM) is to improve the structure and 
effectiveness of PMM data for research and development. The disparity between clinical 
evidence and practice demonstrates a critical need for clinical decision support in 
preoperative medicine. Platform-independent, web-based preoperative decision support 
systems are needed to help meet clinical care guidelines and to improve care delivery.
158
 
Use of health information technology helps improve clinical process quality and quick 
updating of medical knowledge by accessing the evidence-based literature quickly.
159 160
 
The goal of this study is to develop such a system for perioperative medication 
management based on an earlier study 
161
 that addresses the critical information needs of 
clinical providers. In this study we demonstrate how to potentially close the ‘knowing–
doing’ gap by presenting the relevant information to the clinician at the time of decision 
making.
10
 
Workflow Analysis 
In order to gain a thorough understanding of the necessary decision making steps in 
perioperative medication management, we distilled this macro task into several finer 
micro tasks as depicted in Figure 3-1. From the flowchart we discerned that this step 
alone requires a high level of cognitive ability and memory capacity; the provider needs 
to remember what action to take for each medication in the patient’s medication profile.  
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Figure 3-1: Medication management recommendation workflow flowchart 
 
Materials and Methods 
A thorough description of the rules engine of the CDSS has been discussed elsewhere.
161
  
Institutional Review Board approval was sought for this study. It was deemed by the 
authorizing institution that the nature of this work is quality improvement and therefore 
exempt from approval.  
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Setting 
The study was conducted at the Preoperative Medicine Clinic of the Veterans Affairs 
Medical Center (VAMC) in Minneapolis, Minnesota. The Clinic is composed of 10 
clinical providers with a 90% adult male, and 10% adult female patient population. 
Providers and other clinicians use the enterprise-wide VistA Electronic Health Record 
(EHR) system for clinical care. 
Data Sources and Subjects 
In this retrospective descriptive study we sampled electronic medical records of 100 
randomly-selected patients seen at the clinic between 8/1/2010 and 7/31/2012. Each 
patient had been given a comprehensive history and physical exam prior to surgery. Due 
to the relative paucity of females compared to males in the study population, female 
patients were oversampled to better represent a typical clinical population. From each 
patient record, the following data fields were manually extracted and entered into a 
clinical database for heuristics development: type surgery, active medications, medication 
management recommendations (actions), as well as INR (International Normalized Ratio- 
a measure to test blood clotting rate), and creatinine lab values. INR and creatinine values 
were chosen by the clinical reviewers as important data points for their significance in 
reflecting overall liver and kidney health and the ability to metabolize and excrete 
drugs
47
, and were typically completed as part of the preoperative evaluation.  
Development 
System Description and Goals  
We describe our system as a “knowledge-based” expert system focusing “on the 
accumulation, representation, and use of knowledge specific to the particular task” 162 of 
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perioperative medication management recommendations. We used an iterative process of 
design, testing, and revision of the system by a diverse team including informaticians and 
clinical content experts. Here, we describe the process of the method which we used to 
operationalize medication management recommendations into a computer-interpretable 
knowledge base to provide patient-specific recommendations for care. A valuable part of 
our process was collaboration of the developer (MR) directly with the clinical content 
experts to help contextualize recommendations from evidence-base literature and expert 
opinions into recommendations encoded into the CDSS. 
The goals included using evidence-based research to improve practice and promote 
uniformity of care. For our purposes, the CDSS was designed to assist, rather than to 
replace, the clinician in medication management decisions.163 164 Our design strategy was 
threefold: 1) define and code medication management recommendation concepts using a 
“rules” knowledge base, 2) acknowledge that there are limits to how much a CDSS can 
“know” about a patient compared with the provider, and 3) not alienate clinicians by 
making recommendations that unnecessarily limit therapeutic choices. 
We based our system on the iterative process of interim evaluation and testing as in the 
ADDIE (Analysis, Design, Development, Implementation and Evaluation) model 
165
 
(Figure 3-2). 
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Figure 3-2: The ADDIE (Analysis, Design, Development, Implementation, Evaluation) Model 
 
User Interface 
Our system is a web-based system implemented with Python, JavaScript, and HTML 
components. The CDSS user interface (PeriMed) queries the clinician for the patient’s 
medication profile. Once the clinician starts typing the name of a medication, a focused 
list of 20 possible matches, designed to not overrun the screen is displayed in a drop-
down list from which the clinician can choose. This un-fragmented display promotes a 
coherent view of medications as studied by Koppel, et al.
166
 The “pick list” feature of 
PeriMed saves the clinician a substantial amount of data entry time as drug names can get 
lengthy and time-consuming to type (Figure 3-3). 
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Figure 3-3: User can choose drugs from an auto-suggesting dropdown list 
 
The provider can continue entering medications by pressing the  button until all the 
medications have been entered (Figure 3-4).  
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Figure 3-4. Drug entry screen 
 
The  button can be used to remove medications entered in the tool erroneously. 
Once all the medications in the profile have been entered, pressing the  button 
sends the list to the rules engine. The rules engine in turn processes the list, looks up the 
category and class, finds the appropriate rule for medication management, and returns a 
recommendation for each drug entered. If available, link(s) to supporting evidence in the 
literature are also presented (Figure 3-5). Throughout the interaction described, the 
clinician can follow links to relevant citations. 
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Figure 3-5: Medication management recommendation screen. Each recommendation has an evidence level: 
A=RCT study; B=non-RCT study; C=Expert panel opinion; D=non-adjudicated expert opinion (standard of 
care) 
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Evaluation and Classification 
The medication profiles of 100 patients, as described above, were entered into PeriMed, 
and tool-generated outputs were compared manually with corresponding 
recommendations in the EHR notes. The authors believe that this was a representative 
sample size as it contained 92% (33/36) of clinically-significant categories of drugs as 
presented in Cohn, et al.
24
, an authoritative source in perioperative medicine. Medications 
without an explicit management instruction or “NPO (nothing by mouth) after midnight” 
were classified as non-actionable; those with an explicit recommendation (e.g. “take 
A.M. of surgery with a sip of water”) were classified as actionable. Frequency of 
agreement with classification and the specific recommendation between the tool and the 
EHR notes were manually compared. All discrepancies were manually reviewed and 
adjudicated by a domain expert in perioperative medicine and informatics.  
Results 
The distribution of patients per gender per provider is given in Table 3-1. The minimum 
and maximum ages (F/M) were (25/27) and (87/86), respectively.  
Table 3-1: Per-provider patient gender distribution 
Provider #Male Patients #Female Patients Total 
    
1 18 10 28 
2 10 -- 10 
3 15 17 32 
4 16 14 30 
Total 59 41 100 
 
Overall, the sample population used 241 unique drugs from 102 categories representing 
43% (102/237) of drug categories studied in the VA’s formulary. Table 3-2 depicts the 
drug burden statistics in the sample population.  
 41 
 
Table 3-2. Drug burden frequencies in the sample population 
Gender Count Mean Age Total No. of drugs Mean No. of  
Drugs (SE) 
Median No. of 
Drugs  
Mode of No. of 
Drugs 
Female 41 52 340 8.2 (0.7) 8 6 
Male 59 63 539 9.2 (0.7) 8 10 
Total 100 57 879 8.8 (0.5) 8 5 
 
The top ten drug categories accounted for 381 (43%) of all medications in the sample 
population (Figure 3-6).  
Figure 3-6: Top 10 medication categories used by the sample population 
 
The EHR notes contained actions for 43% (n=378) of all medications compared to 56% 
(n=492) in PeriMed, while 39% (n=334) were flagged as actionable in both (Figure 3-7). 
In the non-actionable categories, we found 15% (n=132) flagged in the EHR notes, 2% 
(n=18) by the tool, and 42% (n=369) by both. In 80% (n=82) of categories PeriMed and 
the EHR notes were in 100% agreement. 
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Figure 3-7. Frequency of classification agreements between PeriMed and EHR notes 
 
In the initial pass-through, the tool-generated recommendations agreed with the EHR 
notes 76% (n=665) of the time, averaged over all medications.  
Of particular significance was the accuracy of PeriMed on clinically significant 
medications with corresponding recommendations in Cohn, et al 
24
 (Table 3-3).  
Table 3-3. Tool’s performance for clinically significant medications 
Drug Category  
(VA Class50) 
Cohn, et al.24 
† 
Tool’s†  
Recommendation 
N 
No. of 
matches 
(Tool-EHR) 
% 
Match 
      
Anticoagulants (BL110) 
 
Hold  Hold 2 2 100 
Antiplatelets (BL117) 
 
Hold Hold 29 28 97 
NSAID’s (MS102) 
 
Hold Hold 41 41 100 
COX-2 Inhibitors (MS102) 
 
Hold Hold 1 1 100 
β-Blockers (CV100) 
 
Continue Continue 25 25 100 
α2-Agonists (CV490) 
 
Continue Continue 0 N/A N/A 
α Blockers (CV150) 
 
Continue Continue  15 14 93 
Calcium Channel Blockers (CV200) 
 
Continue Continue 15 15 100 
Nitrates (CV250) 
 
Continue Continue 9 9 100 
ACE Inhibitors (CV800) Hold Hold 17 17 100 
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ARB’s (CV805) 
 
Hold Hold 9 9 100 
Diuretics (CV701) 
 
Hold Hold 15 14 93 
Antiarrhythmics (CV050, CV300) 
 
Continue Continue 3 3 100 
H2 Blockers (GA301) 
 
Continue Continue 7 7 100 
Proton-pump Inhibitors (GA900) 
 
Continue Continue 47 45 96 
Inhaled Bronchodilators (RE102) 
 
Continue Continue 32 32 100 
Corticosteroids (HS051) 
 
Continue Continue 6 6 100 
Insulin (HS501) 
 
Various Various 10 9 90 
Oral Hypoglycemics (HS502) 
 
Hold Hold 16 14 88 
Thyroid Agents (HS851) 
 
Continue Continue 9 9 100 
Oral Contraceptives (HS200) 
 
Hold Hold 0 N/A N/A 
Estrogens (HS300) 
 
Hold Hold 2 0 0 
Antilipemics/Statins (CV350) 
 
Continue Continue 44 9 20 
Antilipemics/Non-Statins (CV350) 
 
Hold Hold 3 1 33 
Opioid Analgesics (CN101) 
 
Continue -- 38 36 95 
Psychotropics (SSRI’s/SNRI’s) (CN609) 
 
Hold Hold 41 30 73 
Psychotropics (Non-SSRI’s/SNRI’s) 
(CN609) 
 
Continue Continue 10 10 100 
Tricyclic Antidepressants (CN601) 
 
Continue Continue 4 4 100 
Benzodiazepines (CN302) 
 
Continue Continue 8 1 13 
Antipsychotic Agents (CN709) 
 
Continue Various 4 4 100 
MAOI’s (CN602) 
 
Hold Hold 0 N/A N/A 
DMARD’s (AN300) 
 
Various Various 2 2 100 
Antigout Agents (MS400) 
 
Continue Continue 4 4 100 
Antiseizure Medications (CN400) 
 
Continue Continue 23 23 100 
Antiparkinson Agents (CN500) 
 
Continue Continue 2 2 100 
Herbal Medications (HA000) Hold Hold 26 24 92 
 
†Broad recommendation; see source for specific exceptions 
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The remaining 24% (n=214) of recommendation discrepancies were manually reviewed 
and adjudicated by one of the authors who is a domain expert in perioperative medicine 
and informatics (TA). The expert identified two areas of discrepancies: 
 Misinterpretation of recommendations in the EHR notes (e.g. a “do nothing” 
recommendation was interpreted as “continue taking”) (n=34) 
 Outright recommendation differences between the tool and the EHR notes (e.g. 
“continue taking” in the EHR notes as opposed to “stop taking” by the tool) 
(n=127) 
In sum, the adjudicator agreed with the tool’s recommendations 69% of the time (n=124). Data 
entry errors were corrected and wording of the disparate recommendations was edited as 
recommended by the external expert. Table 3-4 shows examples of disagreement between 
PeriMed and the EHR notes, and the revisions made to the tool post-adjudication. After the rules 
engine was modified based on the comments from the initial pass-through, we retested the tool a 
second time with the evaluation dataset. In the second round PeriMed generated the appropriate 
recommendation 96% of the time (n=840).  
Table 3-4. Examples of categories of disagreement between PeriMed and EHR notes 
Category 
 Examples of 
disagreement 
 
Resolution by expert 
     
Statins  EHR notes: No action 
Tool: Take A.M. of 
surgery 
 Take P.M. before surgery unless an A.M. dose, in which 
case take A.M. of surgery 
 
 
SSRI’s/SNRI’s 
  
 
EHR notes: Hold A.M. of 
surgery 
Tool: Hold 1-5 days pre-
op 
 
  
 
Consider holding 1-5 days pre-op if risk of bleeding 
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Estrogens 
  
 
EHR notes: No action 
Tool: Hold 4-6 weeks pre-
op 
 
  
 
Hold 4-6 weeks pre-op if risk of DVT 
 
Oral Hypoglycemic 
Agents 
  
 
EHR notes: Hold A.M. of 
surgery 
Tool: Hold P.M. before 
surgery 
  
 
Hold A.M. of surgery 
 
The weighted average of agreement in clinically significant cases was 94%. We 
computed the weighted average because of the significant variability (SD=14) in the 
number of medications in these categories. In the non-clinically significant medications, 
we identified 9 categories with discrepant recommendations. The aggregate match in 
these categories was 71% (32/45). The categories and the corresponding number of 
matches are depicted in Figure 3-8. 
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Figure 3-8: Non-clinically significant Medication Category Agreements 
 
Discussion 
Summary 
We have developed a CDS tool to help perioperative medicine physicians with making 
medication management recommendations during a preoperative physical examination 
evaluation. The tool is an expert system based on a rules engine developed in an earlier 
study by the authors. In processing 879 medications from our sample population, the tool 
(PeriMed) generated the correct (matching the EHR note and/or the external adjudicator) 
recommendation 96% of the time. In clinically significant categories, the accuracy of the 
tool was 94%. This, according to Landis et al 
167
, translates to an “almost perfect” match 
between the clinical experts’ recommendations and the tool’s output. In a substantial 
majority of disparate cases (69%, n=124) between the clinical notes and the tool’s 
1 
9 
2 
3 3 
4 
7 
8 8 
0 
4 
1 
2 2 
3 
6 
7 7 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Aggregate Count 
in Pulled Records 
Medication Category 
n Agreements 
 47 
 
recommendations, an external subject matter expert agreed with the tool’s 
recommendations. Furthermore, our tool performed favorably compared to other similar 
CDSS systems.
168 169
 
It became clear that even simple and relatively straightforward recommendations can be 
interpreted in different ways, depending on one’s perspective or specialty. Much effort 
was spent trying to achieve agreement among our experts about details of the 
recommendations. Although initial efforts tried to put too much specificity into the 
algorithm’s recommendations, we ultimately focused on a more pragmatic goal. This 
goal was simply to ensure that the basic and most important recommendations of 
medication management recommendation practice were being followed, not to pre-
specify every medical decision related to the management of medications, replace the 
clinician, or substitute for the clinician’s education. For example, rather than recommend 
one particular drug (or drug class) over another (which entails factoring in highly 
nuanced patient-specific data that is not stored in or easily accessible from the EHR), we 
decided to implement the more general reminder that the patient simply qualified for 
pharmacologic treatment. Then, by linking to background reference information about the 
mechanism, effectiveness, costs, and side effects of various medications, the autonomy of 
the clinician to make the best decision for the patient was preserved. 
Our system possesses three key features associated with CDSS success as found by 
Kawamoto et al 
37
: 
 The CDSS is electronic rather than paper-based templates 
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 The tool provides decision support at the time and location of care rather than prior to 
or after the patient encounter. 
 The CDSS provides recommendations for care, not just assessments 
As with all evidence-based decision making, clinical judgment and experience factors 
into the process. This system is no exception. Given the scanty nature of strong scientific 
evidence supporting perioperative medication management decision-making, the 
development of this system also relied upon clinical experience and judgment in order to 
stratify the multiple risk factors as well as to provide guidance along the decision 
pathway. 
Elements of perioperative medicine practice have been previously noted to have 
deviation from clinical guidelines for some clinical assessments.
170-172
 Moving toward a 
more evidence-based practice has the potential to improve quality and safety while 
simultaneously reducing costs. We believe that the implementation of computerized 
decision support utilizing EHRs will be a key means with which to improve care practice 
and knowledge. While CDSSs should not replace a provider’s knowledge, experience, 
intuition or judgment, they can complement the clinician’s skills and enhance the quality 
of care provided. Perioperative medication management is an ideal setting for 
development tools that help reduce the incidence of preventable medical errors and 
adverse events given the potential risks of surgical care delivery. These adverse events 
range from potentially stopping a medication that is critical to the patient’s care, or 
perhaps continuing a drug that might interact negatively with anesthesia during the intra-
operative period.  
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Study Limitations 
Our findings are limited in that many of our experiences to date come from a single, 
large, tertiary care institution, and issues in other types of institutions may vary. The 
gender distribution of cases is a limiting factor that was theoretically addressed by the 
oversampling. The lack of full EHR integration is a limiting factor; however, the 
medications are mapped to the drug formulary which makes EHR integration feasible for 
potential future implementation. 
Maintenance and Portability 
One of the core challenges facing PeriMed is difficulty in incorporating the extensive 
quantity of ongoing research on mediation which is being published. In a given year, 
thousands of clinical trials are published many of which have implications for 
perioperative management.
173
 Currently, these studies must be carefully searched, 
retrieved, manually read, evaluated for scientific merit, and incorporated into the CDSS 
in an accurate way. In addition to being laborious, integration of new data can sometimes 
be difficult to quantify or incorporate into the current version of PeriMed, particularly in 
instances where different clinical papers may appear conflicting. To properly resolve 
these sorts of discrepancies often requires carrying out meta-analyses, which often take a 
long time to complete. 
On the other hand, the methodologies with which were developed PeriMed make the tool 
very portable to other care facilities. Software elements used to develop PeriMed are 
platform-independent and web-based; with minimal coding effort PeriMed can become 
operationalized at a care facility within a short period of time. 
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Future Directions 
Caution should be exercised when employing CDS tools such as PeriMed. It should be 
kept in mind that, apart from the drug itself, the patient status, as well as the surgical 
procedure also influences the decision to stop or continue a medication, as well as 
individual patient’s response to medication and the possibility of creating adverse drug 
events.
174-176
 Risks pertaining to each drug should be carefully evaluated. For example, 
several drugs can affect coagulation and discontinuation of others can lead to withdrawal 
symptoms. We speculate that in the future we will incorporate more patient-specific data 
points such as surgery type to the tool in order to enhance the specificity of its 
recommendations.   
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Background: Perioperative medicine data is mostly in non-standard, unstructured free-
text, making the measurement and assessment of clinical outcomes challenging using 
electronic medical record data. Perioperative medication management, managing the 
patient’s medications during the perioperative period, is a complex clinical problem. 
SNOMED CT (Systematized Nomenclature of Medicine Clinical Terms) is a 
comprehensive clinical terminology which provides a consistent way to index, store, 
retrieve, and aggregate clinical data. Our objective was to validate the use of Medication 
Therapy Management (MTM) concepts within SNOMED to express perioperative 
medication management recommendations.  
Methods: Perioperative medication management recommendations of 100 randomly-
selected patients were extracted from their electronic medical records. Keyword searches 
of MTM concepts were performed on the March 2013 of SNOMED CT and candidate 
concepts were manually extracted and verified for relevance by domain experts. Two 
domain experts rated the cross-mappings as a “match” or “non-match”. 
Results: A total of 11 unique recommendations were aggregated from the sample 
population. A search of SNOMED CT yielded 47 concepts. The inter-rater agreement 
statistic between the two experts was 0.77 (substantial). 
Conclusion: MTM concepts in SNOMED CT can be used reliably to code perioperative 
medication management recommendations with sufficient clarity. 
Background 
With an aging U.S. population
1
 there has been a progressive growth in the number of 
surgeries, surgery-related costs, and complications from surgery.
2-5
 At least 50 percent of 
patients undergoing surgery take medications on a regular basis 
6
, and as many as 44% 
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take medications prior to surgery.
25
 Furthermore, half of the general surgical patients take 
medications unrelated to surgery, with a significant increased risk of post-operative 
complications compared to patients taking no medications.
6
  
Perioperative Medication Management (PMM)  
Perioperative medication management (PMM), managing the patient’s active medications 
during the perioperative period, is a complex clinical problem. The state of the 
underlying disease, the risk(s) of withdrawing medication(s), the patient’s response to 
stresses of surgery, the patient’s co-morbidities, and drug-anesthesia interactions are 
factors that the perioperative medicine provider needs to consider for each medication 
recommendation.
24 177
 While the surgical procedural burden in the U.S. is increasing, 
some perioperative medicine providers feel that they are inadequately trained to perform 
preoperative evaluations because until recently, most of the perioperative literature was 
published in a variety of specialty journals. Only in the last few years has more 
information appeared in the general medical literature.
27
 Good medication management 
can improve postoperative outcomes
178
 and plays a key part in successful and safe 
transitions of care
179-181
 as well as the prevention of adverse drug events (ADEs).
182
  
PMM recommendations lack detailed clinical guidelines, resulting in clinical practice 
variations with a variety of provider-specific evaluations. These, in turn, create 
management problems due to practice variation. Besides the paucity of randomized 
clinical trials (RCT) in PMM, perioperative medicine data is mostly in non-standard, 
unstructured free-text, making the measurement and assessment of clinical outcomes 
challenging using electronic health record (EHR) data. Unstructured free-text is not 
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amenable to effective indexing, aggregation, searching, and analysis in EHR systems. 
The meaningful use of EHRs aims to establish the effective use and exchange of health 
care information in order to support better decision making and more effective processes. 
In fact, Stage 2 of Meaningful Use of EHR systems recommends SNOMED CT 
15
 
(Systemized Nomenclature of Medicine Clinical Terms) for structured coding of clinical 
data in EHRs.
16
  
History of SNOMED CT 
Reference terminology development and use is becoming an important aspect of health 
informatics.
183 184
 SNOMED CT is a comprehensive clinical terminology which provides 
a consistent way to index, store, retrieve, and aggregate clinical data across disparate 
specialties and health care facilities, hence reducing variability in data capture and 
encoding.
185
 The structure of SNOMED CT is a hierarchy of concepts and relationships 
which link concepts together.
186
 Support for multiple levels of granularity allows 
SNOMED CT to be used to represent clinical data at a level of detail that is appropriate 
to a range of different uses.
186
 The January 2013 release of SNOMED CT includes more 
than 297,000 active concepts and more than 890,000 logically-defining relationships to 
enable consistency of data documentation, retrieval, and analysis. These numbers suggest 
roughly 39 trillion (2
297,000
 * 890,000) possible combinations of concepts and 
relationships as the upper bound, making a strong case for healthcare data analytics by 
using structured data. 
History of Medication Therapy Management (MTM) 
Medication therapy management (MTM)
187
 is a distinct group of services performed by 
the pharmacist that “optimize therapeutic outcomes for individual patients.” 181 MTM 
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services are distinct from medication dispensing and focus on a patient-centered care.
188
 
Proper documentation of MTM services includes facilitating communication between the 
pharmacist and the patient’s other healthcare professionals regarding recommendations 
intended to resolve or monitor actual or potential medication-related problems.
187
 Similar 
to PMM recommendations, MTM clinical efforts contains a set of medication 
management recommendations, albeit substantially broader. In 2006, two pharmacy 
organizations, the Pharmacist Services Technical Advisory Coalition (PSTAC)
189
 and the 
Pharmacy e-Health Information Technology (HIT) Collaborative
190
, submitted the MTM-
related definitions for proposed codes to SNOMED CT.
191
 Of the submitted set of 
proposed codes, 228 were approved for inclusion, and are now part of the March 2013 
release of SNOMED CT, U.S. edition.  
Significance 
Standardized structured terminology development will be useful to better understand the 
clinical work and associated clinical decisions in PMM. Such a system can enhance 
clinical documentation, data aggregation and integration, inter-practice communication, 
comparative effectiveness research, data exchange, and quality measures.
192 193
 
Furthermore, The Joint Commission requires the use of terminologies in EHR systems.
194
 
Standardized healthcare terminologies are essential in the development of electronic 
health record information and to facilitate quality, safety, and outcomes research.
195
 In 
this article we describe a validation study of using MTM concepts for expressing 
medication management recommendations in the context of surgical planning. 
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Methodology 
Study Objectives 
The main objectives of our study were to: 1) validate the use of SNOMED CT concepts 
to express Perioperative Medication Management Recommendations (PMMRs); 2) 
identify any gaps in SNOMED CT in the context of PMMRs; 3) determine the need for, 
and propose any new PMMR concepts to be added to SNOMED CT. 
Study Design  
A retrospective study using secondary EHR data was conducted to validate the use of 
SNOMED-CT concepts to express PMMRs. We manually extracted PMMRs from the 
electronic records of 100 randomly-selected patients where each patient had been given a 
pre-operative medical examination between 8/1/2010 and 7/31/2012. Perioperative 
medication management had been performed for all the patients and recommendations 
were documented in each patient’s record. We defined “medication” to refer to 
prescription and over-the-counter drugs, supplements, and herbal products. Unlike other 
terminology validation studies
196-198
 where the terminology to be validated had existed 
prior to validation, our study was attempting to validate use of concepts from one domain 
of health care (pharmacy) in another domain (perioperative medicine).  
Setting 
The study was conducted at the General Internal Medicine Pre-Operative Clinic, Veterans 
Affairs Medical Center (VAMC) in Minneapolis, Minnesota. The Clinic is comprised of 
10 primary care physicians with an approximately 90% adult male, and 10% adult female 
patient population. Providers and other clinicians use the enterprise-wide VistA EHR 
system for clinical care.  
 56 
 
Standardized Terminology Utilization 
In order to introduce terminology tools in perioperative medicine, the authors found it 
necessary to establish a foundation by defining data elements (medications) and use of 
data (medication management recommendations) upon which to conduct our validation 
study. We determined that the necessary steps in building this foundation are defined in 
the following tasks: 
1. Operational tasks 
a. Collecting medication recommendations 
b. Vetting the set of recommendations through domain experts 
c. Aggregating concepts that are “match candidates” in SNOMED-CT 
d. Cross-mapping recommendations to candidates in SNOMED-CT 
2. Validation tasks 
a. Verifying the validity of the mappings with domain experts 
b. Identifying any gaps that might exist post-mapping 
Operational Tasks 
After removing duplicates, reconciling synonyms, and disambiguating terms by a 
perioperative medicine domain expert, a distilled list of PMMRs was produced. Our 
sample records revealed five top-level medication management recommendations: 1) stop 
medication; 2) take medication; 3) dose-adjust medication; 4) start new medication; and 
5) change to a different medication. Recommendations were further refined to more 
specific subclasses. For example “stop taking 5 days before surgery” contains the “stop” 
recommendation and the “5 days” temporal specificity. 
To cross-map the recommendations, we downloaded the latest release of SNOMED-CT, 
U.S. edition (March 31, 2013) from the National Library of Medicine (NLM)
199
 to 
conduct a manual search of MTM concepts (Figure 4-1). The team was informed by an 
NLM staff member that concepts in this version could not be searched with the latest 
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SNOMED CT browser
200
, the usual medium for searching. Hence, we conducted a 
manual search of the release files using the following keyword terms and phrases: 
medication, drug, prescription, supplement, herb, over-the-counter, dose, stop, 
discontinue, start, initiate, continue, recommend, “Stop/Discontinue Medication/Drug”, 
“Start/Continue Medication/Drug”. 
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Figure 4-1: Cross-mapping of medication management recommendations to concepts in MTM-SNOMED CT 
 
Validation tasks 
We organized all SNOMED CT synonym candidates into separate but semantically 
equivalent subcategories of prescription medications, herbal products, over-the-counter 
medications, and dietary supplements. The rationale behind subdividing was due to the 
fact that perioperative medication management recommendations are category-agnostic. 
For example, the recommendation “Hold fish oil for 7 days before surgery” does not 
contain any explicit information about the category of medicine (herbal product) to which 
the medication (fish oil) belongs. This meant that for every PMM concept we collected 
several synonym candidates in SNOMED CT. Figure 4-2 depicts one such example of a 
one-to-many mapping. 
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Figure 4-2: One-to-many mappings between perioperative medication management recommendations and 
SNOMED CT concepts 
 
 
We compiled a list of all the PMM concepts with their synonym candidates in a two-
column text file format. In the first column we entered the PMM concept; the second 
column contained synonym candidates. To verify the validity of the mappings, we 
enrolled two domain experts in internal medicine to review the mappings and score each 
mapping as a “match” or “non-match”. The inter-rater reliability statistic (Cohen’s kappa) 
was then calculated for the two raters. The kappa statistic tests inter-rater independence 
between chance alone (kappa=0) and complete agreement (kappa=1). Landis et al
167
 offer 
the following interpretation of inter-rater agreement:  
 
 
0.00 – 0.2 (slight) 
0.21 – 0.40 (fair) 
0.41 – 0.60 (moderate) 
0.61 – 0.80 (substantial) 
0.81 – 1.00 (almost perfect) 
κ =  
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Gap Identification 
Perioperative medication management makes extensive use of temporal concepts such as 
“one day prior”. Although SNOMED CT contains atomic temporal concepts pertinent in 
perioperative medication management (e.g. one, two… ten, day, week, before, after), 
simply combining these concepts with recommendation concepts in MTM will not 
produce the desired results given the SNOMED CT concept model and expression syntax 
for post coordination.
201
 This implies that any recommendation containing a temporal 
concept cannot in fact be fully expressed in SNOMED.  
Results 
After manually searching through the notes, collecting all medication management 
recommendations, and removing duplicates and resolving ambiguities, a total of 11 
unique recommendations were aggregated from the records of the sample population. 
Table 4-1 shows all the recommendations and the frequency with which each 
recommendation appeared in the sample. 
Table 4-1: Perioperative medication management recommendations and frequencies in sample patient records 
Medication Management Recommendation (n) 
1. Hold A.M. of surgery (45) 
2. Hold P.M. prior to surgery (9) 
3. Hold perioperatively (17) 
4. Hold for n [hours/days/weeks] prior to surgery (159) 
5. Hold for m [hours/days/weeks] pre-, and n [hours/days/weeks] post-op (16) 
6. Take A.M. of surgery (164) 
7. Take P.M. prior to surgery (3) 
8. Take perioperatively (13) 
9. Take 30-60 minutes pre-op (7) 
10. Take a reduced dose n [hours/days/weeks] before surgery (8) 
11. Take a varied dose n [hours/days/weeks] before [and/or after] surgery (1) 
 
A search of SNOMED CT yielded 47 concepts that were deemed by a domain expert as 
possible synonym candidates for the 11 PMM recommendations. For each PMM 
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recommendation the number of synonym candidates ranged from a minimum of 1 to a 
maximum of 5. Table 4-2 shows the mappings between PMM recommendations and the 
synonym candidate concept in SNOMED CT for prescription medications. Equivalent 
mappings exist for herbal products, over-the-counter medications and supplements (see 
Appendix 2).  
Table 4-2: Cross-mappings between PMM and MTM-SNOMED CT for prescription medication 
Medication Management Recommendation  SNOMED-CT Concept (CONCEPTID) 
1. Hold A.M. of surgery  
2. Hold P.M. prior to surgery  
3. Hold perioperatively  
4. Hold for n [hours/days/weeks] prior to surgery  
5. Hold for m [hours/days/weeks] pre-, and n 
[hours/days/weeks] post-op  
 
6. Take A.M. of surgery  
7. Take P.M. prior to surgery  
8. Take perioperatively 
9. Take 30-60 minutes pre-op 
 
10. Take a reduced dose n [hours/days/weeks] 
before surgery  
 
11. Take a varied dose n [hours/days/weeks] before 
[and/or after] surgery  
 
1-5. Recommendation to discontinue prescription 
medication (4781000124108) 
 
 
 
 
 
6-9. Recommendation to continue a medication 
(4761000124103) 
 
 
 
10. Recommendation to decrease medication dose 
(428801000124104) 
 
11. Recommendation to change medication dose 
(428791000124100) 
 
 
 After collecting their answers we calculated the inter-rater agreement statistic between 
the two experts. Extent of inter-rater reliability on our test was kappa = 0.77 (substantial). 
Since there was no natural ordering of the data, we believe the kappa value accurately 
reflects the reliability of the mappings.  
Discussion 
We conducted a study to validate the use of structured terminology concepts in pharmacy 
to express clinical procedures. By manually extracting, examining, and vetting MTM 
concepts in SNOMED CT we were able to show that they can be used to code 
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perioperative medication management recommendations with sufficient clarity. Re-use of 
existing machine-interpretable concepts from one domain (pharmacy) in another domain 
(perioperative medicine) was shown to be sufficiently reliable.  
We propose the possible use of SNOMED CT concepts in the Notes section of the VistA 
EHR system for perioperative physical examinations. The purpose is to enhance patient 
safety, decision support capability for clinicians, and error free data transmitted across 
healthcare facilities. 
One caveat which remains, however, is that temporal concepts (e.g. “one day”) which are 
normally part of PMM recommendations are not present in pre-coordinated form in 
SNOMED CT. The post-coordination feature of SNOMED – the feature that allows 
combining of atomic concepts for building more complex concepts- was investigated in 
this study as a possible solution for fully expressing PMM recommendations. Following 
the rules of post-coordination
201
 and in compliance with the SNOMED CT concept model 
and expression syntax would only allow the temporal concept in a recommendation (e.g. 
“one day” in “recommendation to stop taking medication one day prior to surgery”) to be 
applied to the action (i.e. stop taking medication), not the recommendation. It is unlikely 
that Representational forms for expressions will be altered in SNOMED to accommodate 
expressing temporal concepts in PMM. Perhaps these concepts will remain as free-text in 
EHR notes for the foreseeable future. 
Study Limitations 
This was a single-site study with a specific patient population, and medication 
recommendations were limited to the clinical context in the perioperative period. Also, 
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our sample size may not have captured all possible medication management 
recommendations. However, we feel confident that the recommendations captured are 
representative. In the absence of a working SNOMED browser we were unable to 
validate the placement of the MTM concepts in the SNOMED CT hierarchy.  
Future Directions 
Our cross-mappings did not consider the possibility of “partial match” scorings. This is 
due to the fact that SNOMED-CT concepts lacked the temporal axis present in PMM 
concepts (e.g., while “Recommendation to Discontinue Prescription Medication” was a 
match, the timeline on how long to stop a medication was not). For instance, discontinue 
in the context of “Recommendation to discontinue prescription medication” 
(CONCEPTID=4781000124108) is arguably problematic since there is not a clear 
mechanism to restart the medication. There is likely a need to tether the “stop” 
recommendation in SNOMED with a “start/restart” term. This is one of the core 
problems in clinical care transitions where the system should provide some sort of HIT-
driven memory to help manage appropriate continuity.  
Conclusion 
We showed that as computerized health care systems are becoming more knowledge-
intensive and the representation of medical knowledge in a format that is computable as 
well as human readable is becoming more necessary, we need to find ways to start 
expressing clinical thoughts in standardized medical terminologies. SNOMED CT has 
been proven to be an excellent mechanism via which we can accomplish this task.  
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The findings in this study are comparable to other similar studies which assessed the use 
of SNOMED CT for expressing clinical terms and encounters reliably.
198 202
 However, 
SNOMED CT is less-suitable for representing the full extent of information collected in 
perioperative medication management recommendation notes. 
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Chapter 5  
Conclusion 
 
Developing high quality information systems capable of supporting research and clinical 
care in perioperative medicine requires the existence of robust Clinical Decision Support 
(CDS) tools and the use of standardized terminologies which have proven to be effective 
for Health Information Exchange (HIE). These informatics tools must be robust enough 
to have the capability of delivering the right information for the right patient at the right 
time. The studies we conducted in the preceding chapters identified gaps in two areas of 
perioperative medicine: 1) making the best-known medication management 
recommendation during a pre-op physical evaluation; 2) lack of standardized terminology 
concepts to express these recommendations. We therefore offered specific solutions- 
through established research methodologies- on how to address narrowing these gaps. 
Our findings revealed that noticeable differences exist in choosing from several 
medication management recommendations among perioperative medicine providers. This 
is largely due to the fact that practice is provider-specific, lacking any large body of 
research or a determined pool of trusted sources for support. We also discovered that 
these recommendations- when entered in the patient’s record- are in free-text format, 
making them virtually unusable for statistical and outcomes research.  
To address the first gap, the first study developed a methodology and framework for 
building a CDSS knowledge engine based on trusted medical sources (evidence-base 
research, expert opinions, and actual EHR notes). This engine holds medication 
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management recommendations for all of the Veterans Affairs drug formulary containing 
approximately 9,000 drugs in 409 categories. This engine served as the main component 
for development of the full CDSS in the second study. 
In the second study we developed the necessary web-based software components 
independent of any particular hardware platform, in order to operationalize the 
knowledge engine developed in the previous study into a fully functioning decision 
support system. We then utilized established qualitative and quantitative methodologies 
to assess the accuracy of the CDSS in the context of making suitable medication 
management recommendations during a pre-op physical examination evaluation. Our 
findings showed the CDSS performed at a very high accuracy averaged across all patient 
medications sampled, which compares favorably with similar decision support tools. We 
thus concluded that our CDSS can be used effectively in a clinical setting. 
Having developed and evaluated a decision support system in the previous two studies, 
we turned our attention to health information exchange in the third and final study. This 
study evaluated the use of SNOMED CT 
15
 for expressing medication management 
recommendations. Currently, these recommendations are stored in free-text, 
incomputable format.  Hypothesizing that existing medication-related recommendations 
in SNOMED CT can be used, we converted all recommendations from our sample 
records into terminology concepts. Using quantitative statistical methods and qualitative 
adjudication processes, this study yielded a high inter-rater agreement as the measure of 
effective use of SNOMED CT in lieu of free-text.   
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Taken as a whole, these studies have shown significant gaps in uniformity of practice and 
use of computable constructs to express medication management recommendations. 
Narrowing these gaps will provide the ability to provide decision support in perioperative 
medication management. Furthermore, utilizing structured terminologies to express 
concepts, and activities related to medication management is essential to the provision of 
high quality care in perioperative medicine. 
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Appendix 1: Eliminated Drug Categories 
 
Eliminated 
Classes Eliminated Categories 
AD200 CYANIDE ANTIDOTES 
AD400 ANTIDOTES,DETERRENTS,AND POISON CONTROL EXCHANGE RESINS 
AM550 METHENAMINE SALTS ANTIMICROBIALS 
AN200 ANTINEOPLASTIC ANTIBIOTICS 
AN600 ANTINEOPLASTIC RADIOPHARMACEUTICALS 
AN700 PROTECTIVE AGENTS 
AS000 ANTISEPTICS/DISINFECTANTS 
BL115 THROMBOLYTICS 
BL116 ANTIHEMORRHAGICS 
BL500 BLOOD DERIVATIVES 
BL800 VOLUME EXPANDERS 
BL900 BLOOD PRODUCTS,OTHER 
CN200 ANESTHETICS 
CN201 ANESTHETICS,INHALATION 
CN202 BARBITURIC ACID DERIVATIVE ANESTHETICS 
CN203 GENERAL ANESTHETICS,OTHER 
CN204 LOCAL ANESTHETICS,INJECTION 
CN205 ANESTHETIC ADJUNCTS 
CN301 BARBITURIC ACID DERIVATIVE SEDATIVES/HYPNOTICS 
CV600 SCLEROSING AGENTS 
CV709 DIURETICS,OTHER 
DE101 ANTIBACTERIAL,TOPICAL 
DE102 ANTIFUNGAL,TOPICAL 
DE103 ANTIVIRAL,TOPICAL 
DE109 ANTI-INFECTIVE,TOPICAL,OTHER 
DE200 ANTI-INFLAMMATORY,TOPICAL 
DE250 ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS,TOPICAL 
DE300 SUN PROTECTANTS/SCREENS,TOPICAL 
DE350 EMOLLIENTS 
DE400 SOAPS/SHAMPOOS/SOAP-FREE CLEANSERS 
DE450 DEODORANTS/ANTIPERSPIRANTS,TOPICAL 
DE500 KERATOLYTICS/CAUSTICS,TOPICAL 
DE600 ANTINEOPLASTIC,TOPICAL 
DE650 ANALGESICS,TOPICAL 
DE700 LOCAL ANESTHETICS,TOPICAL 
DE752 ANTIACNE AGENTS,TOPICAL 
DE820 ANTIPSORIATICS,TOPICAL 
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DE900 DERMATOLOGICALS,TOPICAL OTHER 
DX101 NON-IONIC CONTRAST MEDIA 
DX102 IONIC CONTRAST MEDIA 
DX109 CONTRAST MEDIA, OTHER 
DX200 RADIOPHARMACEUTICALS,DIAGNOSTIC 
DX201 IMAGING AGENTS (IN VIVO) RADIOPHARMACEUTICALS 
DX202 NON-IMAGING AGENTS RADIOPHARMACEUTICALS 
DX300 DIAGNOSTIC ANTIGENS 
DX900 DIAGNOSTICS,OTHER 
GA400 TUMOR NECROSIS FACTOR BLOCKER 
GU300 ANTI-INFECTIVES,VAGINAL 
GU500 ESTROGENS,VAGINAL 
HS701 ANTERIOR PITUITARY 
HS702 POSTERIOR PITUITARY 
IM100 VACCINES 
IM105 TOXOIDS 
IM109 VACCINES/TOXOIDS, OTHER 
IM300 ANTIVENINS/ANTITOXINS 
IM400 IMMUNE SERUMS 
IM500 IMMUNOGLOBULINS 
IP100 INTRAPLEURAL SCLEROSING AGENTS 
IR100 IRRIGATION SOLUTIONS 
IR200 PERITONEAL DIALYSIS SOLUTIONS 
IR300 HEMODIALYSIS SOLUTIONS 
MS140 PENICILLAMINE 
MS160 GOLD COMPOUNDS,ANTIRHEUMATIC 
MS205 VESICULAR MONOAMINE TRANSPORT TYPE 2 BLOCKER 
MS300 NEUROMUSCULAR BLOCKING AGENTS 
NT900 NASAL AND THROAT,TOPICAL,OTHER 
OP103 ADRENERGICS,TOPICAL OPHTHALMIC 
OP300 ANTI-INFLAMMATORIES,TOPICAL OPHTHALMIC 
OP400 CONTACT LENS SOLUTIONS 
OP500 EYE WASHES/LUBRICANTS 
OP700 ANESTHETICS,TOPICAL OPHTHALMIC 
OR100 CARIOSTATICS,TOPICAL 
OR200 DENTAL PROTECTANTS 
OR300 DENTIFRICES 
OR400 DENTURE ADHESIVES 
OR500 MOUTHWASHES 
OR900 DENTAL AND ORAL AGENTS,TOPICAL,OTHER 
OT101 ANTIBACTERIALS,TOPICAL OTIC 
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OT109 ANTI-INFECTIVES,TOPICAL OTIC OTHER 
OT200 ANTI-INFLAMMATORIES,TOPICAL OTIC 
OT250 ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS,TOPICAL OTIC 
OT400 ANALGESICS,TOPICAL OTIC 
OT900 OTIC AGENTS,OTHER 
PH000 PHARMACEUTICAL AIDS/REAGENTS 
RE600 NON-ANESTHETIC GASES 
TN101 IV SOLUTIONS WITHOUT ELECTROLYTES 
TN102 IV SOLUTIONS WITH ELECTROLYTES 
TN200 ENTERAL NUTRITION 
TN470 FLUORIDE 
TN476 BICARBONATES 
TN501 AMINO ACIDS/PROTEINS,PARENTERAL,WITHOUT ADDED ELECTROLYTES 
TN502 AMINO ACIDS/PROTEINS,PARENTERAL,WITH ADDED ELECTROLYTES 
VT107 PANTOTHENIC ACID 
VT503 DIHYDROTACHYSTEROL 
VT701 MENADIOL 
XA000 PROSTHETICS/SUPPLIES/DEVICES 
XA100 BANDAGES/DRESSINGS 
XA101 PADS,GAUZE,STERILE 
XA102 PADS,GAUZE,NON-STERILE 
XA103 PADS,NON-ADHERING 
XA104 PADS,GAUZE WITH ADHESIVE 
XA105 PADS,GAUZE WITH MEDICATION ADDED 
XA106 GAUZE,FINE MESH 
XA107 BANDAGE,FILM 
XA108 BANDAGE,ELASTIC 
XA109 BANDAGE,STRETCH 
XA110 FOAM WITH ADHESIVE 
XA111 PACKING,GAUZE,PLAIN 
XA112 PACKING,GAUZE,MEDICATED 
XA199 BANDAGES/DRESSINGS,OTHER 
XA201 TAPE,PAPER 
XA202 TAPE,CLOTH 
XA203 TAPE,PLASTIC 
XA204 TAPE,FOAM 
XA205 STRAPS,MONTGOMERY 
XA206 TAPE,TRACH 
XA299 TAPE,OTHER 
XA301 PADS,BED 
XA304 LINER,RUBBER PANTS 
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XA305 DIAPERS 
XA399 PADS/DIAPERS,OTHER 
XA400 COLOSTOMY/ILEOSTOMY COLLECTION DEVICES 
XA401 BAG,DRAINABLE WITH ADHESIVE,COLOSTOMY/ILEOSTOMY 
XA402 BAG,DRAINABLE WITHOUT ADHESIVE,COLOSTOMY/ILEOSTOMY 
XA403 BAG,CLOSED WITH ADHESIVE COLOSTOMY/ILEOSTOMY 
XA404 BAG,CLOSED WITHOUT ADHESIVE COLOSTOMY/ILEOSTOMY 
XA405 BAG,DISPOSABLE WITH ADHESIVE,COLOSTOMY/ILEOSTOMY 
XA407 SETS,APPLIANCE,COLOSTOMY/ILEOSTOMY 
XA499 COLOSTOMY/ILEOSTOMY COLLECTION DEVICES,OTHER 
XA500 UROSTOMY/URINARY COLLECTION DEVICES 
XA501 BAG,BEDSIDE URINARY COLLECTION DEVICE 
XA502 BOTTLES/OTHER BEDSIDE URINARY COLLECTION DEVICES 
XA503 SETS,APPLIANCE,UROSTOMY 
XA504 BAG,DRAINABLE WITH ADHESIVE,UROSTOMY 
XA505 BAG,DRAINABLE WITHOUT ADHESIVE,UROSTOMY 
XA507 BAG,CLOSED WITHOUT ADHESIVE,UROSTOMY 
XA508 BAG,LEG URINARY COLLECTION DEVICE 
XA509 CATHETER,FOLEY 
XA510 CATHETER,COUDE-TIP 
XA511 CATHETER,BALLOON 
XA512 CATHETER,RED RUBBER 
XA513 CATHETER,EXTERNAL URINARY 
XA515 KIT,CATHETER CARE 
XA516 SET,IRRIGATION 
XA599 UROSTOMY/URINARY COLLECTION DEVICES,OTHER 
XA600 OSTOMY SUPPLIES,OTHER 
XA601 RINGS,OSTOMY 
XA602 DISCS,OSTOMY 
XA603 ADHESIVES,OSTOMY 
XA604 PROTECTANTS,SKIN,OSTOMY 
XA605 BELTS,OSTOMY 
XA606 ODOR CONTROL PRODUCTS,OSTOMY 
XA607 IRRIGATORS/SETS,OSTOMY 
XA608 CAPS,OSTOMY 
XA699 OSTOMY SUPPLIES,OTHER 
XA701 BAGS,FEEDING 
XA703 TUBES,FEEDING 
XA799 BAGS/TUBES/SUPPLIES FOR ORAL NUTRITION,OTHER 
XA801 SETS,VOLUMETRIC,INTRAVENOUS 
XA802 SETS,MAXI-DRIP,INTRAVENOUS 
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XA805 SETS,BUTTERFLY,INTRAVENOUS 
XA809 INTRAVENOUS SETS,OTHER 
XA850 SYRINGES/NEEDLES 
XA851 SYRINGES,SLIP TIP,INJECTION 
XA852 SYRINGES,LUER LOCK,INJECTION 
XA853 SYRINGES WITH NEEDLE,INJECTION 
XA854 SYRINGES,INSULIN,INJECTION 
XA855 CAPS,SYRINGE 
XA856 NEEDLES,INJECTION 
XA859 SYRINGES/NEEDLES,OTHER 
XA900 SUPPLIES,OTHER 
XX000 MISCELLANEOUS AGENTS 
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Appendix 2: SNOMED CT Medication Management Concept 
Candidates 
 
CONCEPTID FULLYSPECIFIEDNAME 
 
182838006 Change medication (procedure) 
 
432811000124101 Change medication course (procedure) 
 
432841000124102 Change medication dosage form (procedure) 
 
432751000124106 Change medication dose (procedure) 
 
432781000124103 Change medication dosing interval (procedure) 
 
407611006 Change medication to generic equivalent (procedure) 
 
432901000124105 Change medication to therapeutic equivalent (procedure) 
 
432911000124108 Change medication to therapeutic equivalent on formulary 
(procedure) 
 
432771000124101 Decrease medication dose (procedure) 
 
432791000124100 Decrease medication dosing interval (procedure) 
 
432761000124108 Increase medication dose (procedure) 
 
432801000124104 Increase medication dosing interval (procedure) 
 
432821000124109 Lengthen medication course (procedure) 
 
428711000124105 Recommendation to change medication (procedure) 
 
428721000124102 Recommendation to change medication course (procedure) 
 
428791000124100 Recommendation to change medication dose (procedure) 
 
428751000124106 Recommendation to change medication dose form (procedure) 
 
428761000124108 Recommendation to change medication dosing interval (procedure) 
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428831000124107 Recommendation to change medication to generic equivalent 
(procedure) 
 
428841000124102 Recommendation to change medication to therapeutic equivalent 
(procedure) 
 
428851000124100 Recommendation to change medication to therapeutic equivalent on 
formulary (procedure) 
 
4761000124103 Recommendation to continue a medication (procedure) 
 
306806004 Recommendation to continue medication (procedure) 
 
428801000124104 Recommendation to decrease medication dose (procedure) 
 
428781000124103 Recommendation to decrease medication dosing interval 
(procedure) 
 
4711000124101 Recommendation to discontinue dietary supplement (procedure) 
 
4791000124106 Recommendation to discontinue herbal supplement (procedure) 
 
4701000124104 Recommendation to discontinue medication (procedure) 
 
304540007 Recommendation to discontinue medication (procedure) 
 
4801000124107 Recommendation to discontinue over-the-counter medication 
(procedure) 
 
4781000124108 Recommendation to discontinue prescription medication (procedure) 
 
428811000124101 Recommendation to increase medication dose (procedure) 
 
428771000124101 Recommendation to increase medication dosing interval (procedure) 
 
428881000124108 Recommendation to initiate laboratory results monitoring 
(procedure) 
 
428871000124105 Recommendation to initiate medication monitoring (procedure) 
 
428741000124109 Recommendation to lengthen medication course (procedure) 
 
428731000124104 Recommendation to shorten medication course (procedure) 
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4831000124104 Recommendation to start dietary supplement (procedure) 
 
4821000124102 Recommendation to start herbal supplement (procedure) 
 
428861000124103 Recommendation to start medication therapy (procedure) 
 
4811000124105 Recommendation to start over-the-counter medication (procedure) 
 
428821000124109 Recommendation to start prescription medication (procedure) 
 
432831000124107 Shorten medication course (procedure) 
 
432871000124105 Start dietary supplement (procedure) 
 
432881000124108 Start herbal supplement (procedure) 
 
432851000124100 Start over-the-counter medication (procedure) 
 
432861000124103 Start prescription medication (procedure) 
 
 
